Drug Trial Radar · NCT04394351
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Sep 1, 2020
Primary completion
Jun 2, 2022
Study completion May 14, 2024
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- May 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria. The Secondary objectives are: * To demonstrate the efficacy of dupilumab compared to placebo in pediatric patients with active EoE after 16 weeks of treatment as assessed by endoscopic visual measurements of disease activity using the Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFS) and histologic abnormalities as measured by the EoE Histology Scoring System (EoE-HSS) * To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 16 weeks in pediatric patients with active EoE * To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation * To study the effects of dupilumab on the type 2 inflammation gene expression signature * To evaluate the concentration-time profile of functional dupilumab in serum in this population * To assess efficacy of long-term (up to 160 weeks) dupilumab treatment * To assess the impact of dupilumab treatment on changes in weight and growth during the extended active period and open-label extension period of the study * To assess safety, tolerability, and immunogenicity of long-term (up to 160 weeks) dupilumab treatment * To evaluate the impact of dupilumab treatment on EoE signs and symptoms
Conditions
- Eosinophilic Esophagitis (EoE)
Interventions
DupilumabDrug
Single-use, prefilled syringe
Matching PlaceboDrug
Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16Time frame: At Week 16
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Regeneron Study Site
Phoenix, Arizona
Regeneron Study Site
Little Rock, Arkansas
Regeneron Study Site
Los Angeles, California
Regeneron Study Site
San Francisco, California
Regeneron Study Site
Aurora, Colorado
Regeneron Study Site
St. Petersburg, Florida
Regeneron Study Site
Atlanta, Georgia
Regeneron Study Site
Atlanta, Georgia
Regeneron Study Site
Chicago, Illinois
Regeneron Study Site
Indianapolis, Indiana
Regeneron Study Site
Iowa City, Iowa
Regeneron Study Site
Boston, Massachusetts
Regeneron Study Site
Boston, Massachusetts
Regeneron Study Site
Boston, Massachusetts
Regeneron Study Site
Lincoln, Nebraska
Regeneron Study Site
New York, New York
Regeneron Study Site
New York, New York
Regeneron Study Site
New York, New York
Regeneron Study Site
Chapel Hill, North Carolina
Regeneron Study Site
Cincinnati, Ohio
Regeneron Study Site
Cleveland, Ohio
Regeneron Study Site
Philadelphia, Pennsylvania
Regeneron Study Site
Dallas, Texas
Regeneron Study Site
Fort Worth, Texas
Regeneron Study Site
Houston, Texas
Regeneron Study Site
Milwaukee, Wisconsin
Regeneron Study Site
London, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.